On issuance, the patent will expire in 2022. The company said that the subsequently filed patent applications which broaden its patent position could extend the patent life for the wound care and breast implant product portfolios until the end of 2026.
Kerry Gray, president and CEO of Uluru, said: “This notice of allowance is an important step in securing intellectual property protection for the range of products we anticipate developing from our nanoparticle aggregate technology. To further secure our patent position we have also filed additional patents to protect the wound care, breast implant and dermal filler applications of the technology.”